Search clinical trials for: Inhaled PT005

Total 1048 results

Pearl Therapeutics, Inc.

Completed

Study to Evaluate Single Inhaled Doses of PT001, PT003, PT005 and PT001 Plus PT005 in Healthy Subjects

Healthy Volunteers

Australia
Pearl Therapeutics, Inc.

Completed

PT003 MDI Dose Confirmation Study

Chronic Obstructive Pulmonary Disease

United States
Pearl Therapeutics, Inc.

Completed

Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD

Chronic Obstructive Pulmonary Disease

United States, Germany, United Kingdom, China, Taiwan, Korea, Republic of, Japan, Czechia, Hungary, Poland, Russian Federation
Pearl Therapeutics, Inc.

Completed

A Study to Assess the Effects of PT001 and PT005 MDI on Specific Image Based Parameters in Subjects With Moderate to Severe COPD

COPD, Chronic Obstructive Pulmonary Disease

Belgium
Pearl Therapeutics, Inc.

Completed

Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United States
Pearl Therapeutics, Inc.

Completed

Phase I Study Evaluating the Safety and Pharmacokinetics of Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (BGF MDI) in Healthy Volunteers

Healthy Volunteers

United States
Pearl Therapeutics, Inc.

Completed

Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)

Chronic Obstructive Pulmonary Disease (COPD)

United States
Gyroscope Therapeutics Limited
Novartis Pharmaceuticals

Active, not recruiting

HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

Dry Age-related Macular Degeneration

United States, Germany, United Kingdom, France, Spain, Australia, Poland
Pearl Therapeutics, Inc.

Completed

PT003 MDI Cardiovascular Safety Study

Chronic Obstructive Pulmonary Disease

United States, Australia, New Zealand
Gyroscope Therapeutics Limited
Novartis Pharmaceuticals

Active, not recruiting

EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005 (EXPLORE)

Dry Age-related Macular Degeneration

United States, Germany, United Kingdom, Spain, Poland, Australia, France, Netherlands
Gyroscope Therapeutics Limited
Novartis Pharmaceuticals

Active, not recruiting

FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD

Eye Diseases | Macular Degeneration | Retinal Degeneration | Geographic Atrophy | Dry Age-related Macular Degeneration | Retinal Disease | Macular Atrophy

United States, United Kingdom
Orion Corporation, Orion Pharma

Completed

Inspiratory Flow Parameters and Handling of Easyhaler and Turbuhaler Inhalers (PIFECO)

Pulmonary Disease, Chronic Obstructive | Asthma

United Kingdom, Finland
Pearl Therapeutics, Inc.

Withdrawn

Efficacy and Safety of Two Doses of Formoterol Fumarate MDI (PT005) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), Compared to Foradil® Aerolizer® as an Active Control

COPD

United States
Pearl Therapeutics, Inc.

Completed

Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®

COPD

Japan
Pearl Therapeutics, Inc.

Completed

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Australia, United States, New Zealand
Pearl Therapeutics, Inc.

Completed

Study to Evaluate the Safety and Efficacy of Inhaled PT001 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States
Pearl Therapeutics, Inc.

Completed

Study to Evaluate the Safety and Efficacy of Inhaled PT005 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Australia, New Zealand
Synspira, Inc.

Terminated

A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis

Lung Diseases | Cystic Fibrosis | Pulmonary Disease | Antibiotic Resistant Infection | Respiratory Tract Disease | Cystic Fibrosis Pulmonary Exacerbation | Lung Inflammation | Burkholderia Infections | Lung Infection | Multi-antibiotic Resistance | Pulmonary Inflammation | Lung Infection Pseudomonal | Cystic Fibrosis... and other conditions

United Kingdom
GlaxoSmithKline

Completed

Study to Assess the Safety and PK of GSK573719 and GSK573719/GW642444(VI) Combination in Healthy Subjects and Subjects With Severe Renal Impairment

Pulmonary Disease, Chronic Obstructive

Czechia, Hungary
GlaxoSmithKline

Completed

A Study to Assess the Effects of GSK573719/VI Combination and GSK573719 Monotherapy in Subjects With Moderate Hepatic Impairment and Matched Healthy Volunteers

Pulmonary Disease, Chronic Obstructive

Hungary, Slovakia
Galecto Biotech AB

Completed

RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients

Idiopathic Pulmonary Fibrosis

United Kingdom
Gyroscope Therapeutics Limited
Novartis Pharmaceuticals

Enrolling by invitation

ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study (ORACLE)

Age Related Macular Degeneration (AMD)

United States, Germany, Spain, France, Australia, United Kingdom
Pearl Therapeutics, Inc.

Completed

Crossover Study to Assess the Efficacy of PT003 With and Without a Valved Holding Chamber in Subjects With Moderate to Severe COPD

COPD

United States
Makerere University
University of Copenhagen

Completed

Inhaled Corticosteroids in U-5 Children With Acute Respiratory Infection in Uganda: A Randomised Trial (ICS)

Bacterial Pneumonia | Acute Asthma | Viral Pneumonia

Uganda
GlaxoSmithKline

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2339345.

Cough

United Kingdom
Boehringer Ingelheim

Completed

The OPTI Study in Spain Looks at the History Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Inhaled Steroids.

Pulmonary Disease, Chronic Obstructive

Spain
Liquidia Technologies, Inc.
Nuventra, Inc.

Completed

Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil (INSPIRE)

Primary Pulmonary Hypertension

United States
National Heart, Lung, and Blood Institute (NHLBI)
Childhood Asthma Research and Education Network

Completed

Prevention of Early Asthma in Kids (PEAK)

Lung Diseases | Asthma
Liquidia Technologies, Inc.
Nuventra, Inc.

Active, not recruiting

Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil

Primary Pulmonary Hypertension

United States
Alexza Pharmaceuticals, Inc.

Completed

Staccato Prochlorperazine in Migraine (Out Patient)

Migraine Headache | Aura

United States
Pearl Therapeutics, Inc.

Completed

A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos)

Chronic Obstructive Pulmonary Disorder

United States, Austria, Belgium, Canada, Denmark, Germany, Italy, Spain, Sweden, United Kingdom, Peru, Brazil, South Africa, Argentina, Russian Federation, Mexico, Puerto Rico, Chile, Norway
Ajou University School of Medicine
AstraZeneca

Recruiting

Long-term Effect of Steroid on Metabolic Diseases in Asthmatics

Asthma | Osteoporosis Risk | Osteoporotic Fractures | Osteoporosis, Osteopenia

Korea, Republic of
GlaxoSmithKline

Completed

WEUKBRE5554: IMI PROTECT(Work Package 2): Beta2 Agonists and Acute Myocardial Infarction

Asthma
Pearl Therapeutics, Inc.

Completed

Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Australia, New Zealand
Massachusetts General Hospital
Rezoagli, Emanuele, M.D., Massachusetts General Hospital, Harvard Medical... and other collaborators

Active, not recruiting

Prolonged Hypoxic Breathing in Healthy Volunteers: a Safety Study (MGH-nitrogen)

Healthy Volunteers

United States
Washington University School of Medicine
Barnes-Jewish Hospital

Completed

Controlled Clinical Trial of Supplemental Oxygen for the Prevention of Post-Cesarean Infectious Morbidity (Peri-Op)

Surgical Wound Infection | Endometritis | Infection; Cesarean Section

United States
Aridis Pharmaceuticals, Inc.

Recruiting

SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects

Cystic Fibrosis

United States
Pearl Therapeutics, Inc.

Completed

A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos) (KRONOS)

COPD

United States, Canada, China, Japan
Imperial College London

Completed

Measuring Hydrogen Peroxide in Exhaled Breath Condensate in HV

Proof Of Concept Study

United Kingdom
Liquidia Technologies, Inc.
FGK Clinical Research GmbH

Terminated

Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil

Pulmonary Arterial Hypertension

France, Germany
ISBRG Corp
National Advanced Driving Simulator

Recruiting

Detection of Cannabis Impairment With ISBRG's SpotLight-THC

Cannabis

United States
Novartis

Completed

A Study to Assess the Efficacy of Inhaled Corticosteroid (ICS) Therapy in Moderate-Severe Bronchial Asthma

Bronchial Asthma

Germany
Parc de Salut Mar

Active, not recruiting

Asthma Research in Children and Adolescents (ARCA)

Asthma in Children | Persistent Asthma | Asthma Exacerbation

Spain
Pearl Therapeutics, Inc.

Terminated

Study to Evaluate the Treatment Effect of PT003 on Cardiovascular Hemodynamics in Subjects With Moderate to Severe COPD

COPD

United States
University of North Carolina, Chapel Hill
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Study of Dust Mite Inhalation in Humans

Allergy | Mild Asthma

United States
Children's National Research Institute

Completed

Improving Pediatric Asthma Care Through Inhaled Steroids in Schools (ISIS)

Asthma
University of Toronto
University Health Network, Toronto; Thornhill Research

Unknown

The Response of Intraocular Pressure to Systemic Hypercapnia and Hyperoxia

Intraocular Pressure

Canada
Pearl Therapeutics, Inc.

Completed

24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003 and Placebo MDI

COPD
Yonsei University

Not yet recruiting

Effects of Iloprost on Oxygenation During One-lung Ventilation in Supine-positioned Patients

Mediastinal Mass

Korea, Republic of
Alexza Pharmaceuticals, Inc.

Completed

Staccato Loxapine Single Dose PK

Schizophrenia

United States

Search clinical trials for: Inhaled PT005

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations